Revenue: As of FY2025 Q2, the actual value is USD 301 K.EPS: As of FY2025 Q2, the actual value is USD -0.24.EBIT: As of FY2025 Q2, the actual value is USD -29.73 M.<h3>Segment Revenue</h3><ul><li>Product Revenue, Net: $0.1 million for the three months ended June 30, 2025, and $0.2 million for the six months ended June 30, 2025, from sales of Symvess in the United States.</li><li>Contract Revenue: $0.2 million for the three months ended June 30, 2025, and $0.6 million for the six months ended June 30, 2025, related to research and development services.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income (Loss): Net loss of $37.7 million for the three months ended June 30, 2025, compared to a net loss of $56.7 million for the same period in 2024. Net income of $1.5 million for the six months ended June 30, 2025, compared to a net loss of $88.6 million for the same period in 2024.</li><li>Research and Development Expenses: $22.0 million for the three months ended June 30, 2025, a decrease from $23.8 million for the same period in 2024. $37.4 million for the six months ended June 30, 2025, a decrease from $45.0 million for the same period in 2024.</li><li>Selling, General and Administrative Expenses: $7.8 million for the three months ended June 30, 2025, an increase from $5.7 million for the same period in 2024. $15.9 million for the six months ended June 30, 2025, an increase from $11.1 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $55.0 million for the six months ended June 30, 2025, compared to $48.6 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $48.9 million for the six months ended June 30, 2025, compared to $62.3 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Change in Fair Value of Contingent Earnout Liability: Non-cash gain of $44.3 million for the six months ended June 30, 2025, compared to a non-cash loss of $30.2 million for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to commercialize Symvess in the U.S. for vascular trauma and, if approved, in AV access for hemodialysis. It also aims to obtain marketing approval for its 6 millimeter ATEV in additional indications and expand its manufacturing facility to meet potential market demand.</li><li>Non-Core Business: The company is exploring the application of its technology across a broad range of markets and indications, including the development of urinary conduit, trachea, esophagus, and other novel cell delivery systems.</li></ul>

Humacyte - CW27 | 10-Q: FY2025 Q2 Revenue: USD 301 K